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Abstract
Background: Surface enhanced laser desorption and ionization time-of-flight mass spectrometry
(SELDI-TOF-MS) analysis on serum samples was reported to be able to detect colorectal cancer
(CRC) from normal or control patients. We carried out a validation study of a SELDI-TOF MS
approach with IMAC surface sample processing to identify CRC.
Methods: A retrospective cohort of 338 serum samples including 154 CRCs, 67 control cancers
and 117 non-cancerous conditions was profiled using SELDI-TOF-MS.
Results: No CRC "specific" classifier was found. However, a classifier consisting of two protein
peaks separates cancer from non-cancerous conditions with high accuracy.
Conclusion: In this study, the SELDI-TOF-MS-based protein expression profiling approach did not
perform to identify CRC. However, this technique is promising in distinguishing patients with
cancer from a non-cancerous population; it may be useful for monitoring recurrence of CRC after
treatment.
Background
Colorectal cancer (CRC) is ranked the fourth most fre-
quent cause in cancer-related deaths in China [1]. Pre-
symptomatic screening can detect early-stage cancer while
it is still localized and with potential to be cured, translat-
ing into greatly reduced cancer-related mortality and treat-
ment-related morbidity. Unfortunately, only about 37%
of CRC remain localized at the time of diagnosis [2].
Endoscopic examination of the colon remains the gold
standard for diagnosis; however, it is invasive, unpleasant
and carries risk of morbidity and even mortality. Identifi-
cation of high risk patients using simple, cheap and less
invasive tests would increase the chance to diagnose CRC
at early stage. Carcinoembryonic antigen (CEA) is of
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ited sensitivity (30–40%) for detecting early CRC [3,4],
whereas serial faecal occult blood testing is proven to
reduce CRC mortality but suffers from significant false
negative and false positive rates [5]. Stool DNA analysis of
multiple markers has shown to be a potential method for
screen detection of CRC [6,7]. However, serum-based
assays with equivalent sensitivity and specificity would be
more acceptable to many patients. Specifically, methods
for early detection or identification of aggressive CRC can-
cers need to be investigated and developed [8].
Comparative proteomic profiling coupled with computer-
ized machine learning without the need of actual identifi-
cation of specific proteins recently presented itself as a
rapid and promising alternative method to traditionalsin-
gle protein assays. SELDI-TOF-MS is a technology that can
produce proteomic "fingerprints" from biological sam-
ples using a relatively high throughput platform. SELDI
has been applied in identifying diagnostic markers in
ovarian [9], prostate [10,11], breast [12], bladder [13],
hepatic [14,15] and pancreatic cancer [16] using serum or
plasma. Our and several other small case-control studies
have also reported that, based on protein profiles of
serum, SELDI-TOF MS can be used to separate patients
with CRC from healthy controls [17-19]. Once a biomar-
ker for early detection is identified, specific criteria must
be met before such a biomarker is accepted as clinically
useful following a general process for the identification
and validation [20].
Here we describe the results of a validation study of our
previously reported [19]markers identified by SELDI-TOF
MS for early detection of CRC. This study was designed to
determine whether the SELDI-TOF MS method accurately
predicts the presence of CRC in an independent, case-con-
trol series collected by multiple sites.
Methods
Patients and Specimens
Patient samples were enrolled from 4 hospitals in Beijing
including Beijing Cancer Hospital, Beijing Tongren Hos-
pital, China-Japan Friendship Hospital and Beijing
Friendship Hospital during the period of July 2006
through February 2008. The study was approved by
research ethics committees of these hospitals. After
obtaining informed consent from patients and volunteers,
blood specimens were collected. We used patient infor-
mation to classify samples into 1 of 4 diagnostic groups:
1) CRC; 2) a control group with a history of non-cancer-
ous disease but no history of any cancer type; 3) a control
group without history of CRC, but with other cancer; 4)
healthy volunteers. The number of acceptable specimens
in each group was 154, 45, 67 and 72, respectively. We
selected a random sample of eligible specimens under
restrictions imposed to achieve greatest balance by age
and sex. The demographic information for all collected
samples was provided in Table 1 and contribution of sam-
ples by disease groups from each hospital was shown in
Table 2. The differences in contributions to disease groups
by individual hospital were significant (P < 0.0001, Pear-
son Chi-Square test). As preanalysis sample handling may
affect the results [21], all serum was collected following a
standard procedure as previously described [19].
ProteinChip Processing
On the day of analysis, serum samples were placed on ice
and thawed completely. Any samples that were hemo-
lyzed or visually lipemic were excluded from analysis. All
samples were subjected to the same number of freeze-
thaw cycles.
Because IMAC3 ProteinChip arrays used in our previous
study were not commercially available anymore [19], sera
were analyzed on Cu2+-loaded IMAC30 ProteinChip
arrays (a modified second generation IMAC3) in this
study [22]. Each array was run with at least 1 quality con-
trol (QC) serum sample, leaving 7 wells for specimen
analysis. The QC was a pooled serum sample of 50 volun-
teers, whom were stringently examined to ensure they do
not have hepatitis, renal disease, cancer, inflammatory,
malnutrition, or other diseases that might affect body pro-
tein metabolism. They were required to take no-meat
meals on the day before sample collection, and all the
samples were collected in the morning before food intake.
To eliminate potential confounding of diagnostic groups
Table 1: Patient characteristics
Age Gender Clinical Stage
Sample Group (mean ± SD) P Male Female P I II III IV
CRC (n = 154) 62.52 ± 11.32 84 70 27 50 69 8
OC (n = 67) 59.16 ± 11.71 0.61* 24 43 0.01† 19 18 15 15
N D (n = 45) 58.66 ± 13.56 0.06* 26 19 0.70†
HV (n = 72) 50.54 ± 13.94 0.00* 36 36 0.52†
*Student's t test, compared with CRC; † Pearson Chi-Square test, compared with CRC. OC, other cancer types; ND, non-cancerous disease; HV, 
healthy volunteer.Page 2 of 9
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domly selected samples from different diagnostic groups.
Sample placement was randomized within arrays to elim-
inate array position bias. The IMAC30 chip processing
procedure was as reported [22].
SELDI Spectrum Generation
All chips were analyzed in a single Protein Biological Sys-
tem IIc TOF MS (PBS-IIc, Bio-Rad Laboratories) at Beijing
Cancer Hospital. The mass spectra were obtained using
the following parameters: 175 laser shots/spectra col-
lected in the positive mode; detector sensitivity of 9; and
a detector voltage of 2950 V. Mass accuracy was calibrated
externally using the All-In-One peptide molecular mass
standard (Bio-Rad Laboratories).
Data Processing
Peaks were detected automatically using ProteinChip
Software, version 3.2.1 (Bio-Rad Laboratories). All spectra
were compiled and normalized to the total ion currents
with baselines subtracted. Peaks between m/z 1500 and m/
z 50000 were auto-detected using the Biomarker Wizard
software (BMW, Bio-Rad Laboratories) with a signal-to-
noise ratio of > 5, and the peaks present in > 20% of the
spectra were clustered using second-pass peak selection
with a signal-to-noise ratio of > 2 and mass windows of
0.3% [23].
Classifier Construction
A total of 338 specimens were randomly assigned to train-
ing set and blinded testing set. Patient characteristics of
the two sets were shown in Table 3. There was no statisti-
cal difference between the two sets of samples in age (Stu-
dent's t test, P > 0.05, detailed data not shown), sex, TNM
stage and diagnostic groups from each hospital (Fisher's
exact test, P > 0.05, detailed data not shown). However,
samples of non-cancerous disease from each hospital in
the two set were not evenly distributed because of low
number of subjects from three participating hospitals (P <
0.01, Fisher's exact test). In this study, data were analyzed
to develop three individual classifiers for three objectives.
The first "Cancer- and CRC-specific" classifier was devel-
oped to distinguish patients with CRC from those with
other cancer types, and non-cancerous conditions. The
second "cancer-specific" classifier was intended to differ-
entiate cancer patients from non-cancerous controls, and
the last "CRC-specific" classifier was to distinguish
patients with CRC from those with other cancer types.
Table 2: Number of selected serum samples contributed by each 
hospital, by diagnostic group
Hospital Diagnostic group
Cancer Non-cancerous Control
CRC OC Non-cancerous Disease Healthy Volunteer
BCH 67 67 5 0
BTH 24 0 3 4
CJFH 25 0 15 57
BFH 38 0 22 11
Total 154 67 45 72
BCH, Beijing Cancer Hospital; BTH, Beijing Tongren Hospital; CJFH, 
China-Japan Friendship Hospital; BFH, Beijing Friendship Hospital; 
OC, other cancer types.
Table 3: Patient characters of the training set and test set
Training Set Blinded Test Set
CRC (n = 78) Control (n = 89) CRC (n = 76) Control (n = 95)
OC ND HV OC ND HV
33 19 37 34 26 35
Gender
Male 41 13 10 17 43 11 16 19
Female 37 20 9 20 33 23 10 16
Clinical Stage
I 13 8 14 11
II 26 8 24 10
III 35 9 34 6
IV 4 8 4 7
Hospital
BCH 35 33 4 0 32 34 1 0
BTH 9 0 3 1 15 0 0 3
CJFH 11 0 9 32 14 0 6 25
BFH 23 0 3 4 15 0 19 7
OC, other cancer types; ND, non-cancerous disease; HV, healthy volunteer. BCH, Beijing Cancer Hospital; BTH, Beijing Tongren Hospital; CJFH, 
China-Japan Friendship Hospital; BFH, Beijing Friendship Hospital.Page 3 of 9
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Rad Laboratories) was used to analyze the proteomic fea-
tures of the training set data. This software has the ability
to combine multiple biomarkers to identify and distin-
guish any independent groups, thereby increasing sensi-
tivity and specificity compared with single biomarker
predictors [24]. A decision tree was generated by using the
Gini method with non-linear combinations [23]. Multi-
ple trees were initially generated from 167 samples by
adjusting the splitting factor with increments of 0.1. A 10-
fold cross-validation analysis was carried out as an initial
evaluation of the test error of these trees [24]. The peaks
forming the main splitters of the tree with the highest pre-
dictive rates were selected, and the tree was rebuilt based
on these peaks alone and evaluated by the test set. P-val-
ues were calculated on the basis of t-test (BMW software).
A P-value of less than 0.05 was considered statistically sig-
nificant. The validity and accuracy of the best tree was
then challenged by the blinded testing set. The samples in
the blinded testing set were arranged randomly and their
origins were unknown to the technicians who processed
them. The same method was used to construct the second
decision tree classifier to distinguish cancer patients from
non-cancerous controls. Using the cancer specimens in
the training set; we then tried to construct the third deci-
sion tree classifier to distinguish CRC from the other two
cancer types.
Statistical analysis
Statistically significant differences were detected using the
Pearson Chi-Square test and the Student's t test. Analysis
was performed with SPSS 13.0 for Windows (SPSS Inc).
Receiver operator characteristics (ROC) curves were gener-
ated and the area under the curve (AUC) values was calcu-
lated using this same software.
Results
Assay Reproducibility
The reproducibility of the assay was estimated by using
QC samples. 18 protein peaks in the molecular weight
range from m/z 1,500 to m/z 50,000, and the intensity
range of 10–60 were selected randomly to calculate the
intra-array and inter-array CV. The intra-array and inter-
array CV for mass accuracy were both 0.03%, and for the
normalized intensity were ≤ 10% and ≤ 20%, respectively
(data not shown).
The Classifier Derived from Previous Study Failed to 
Discriminate CRC Patients from Control Conditions
We previously reported a classifier (composed of two
peaks: m/z 8,132 and m/z 4,002) to discriminate CRC
patients from healthy volunteers [19]. However, this clas-
sifier failed to discriminate CRC patients from healthy
volunteers in cohorts of the current study. We then seek to
explore reasons for this discrepancy. We used QC samples
to generate peaks from an IMAC30 array and a previously
preserved IMAC3 array respectively, with the same experi-
mental procedure mentioned above. The m/z drift
between the two arrays was less than 0.03%; but the inten-
sities of peaks generated from the two arrays were of great
difference (Figure 1), which might be part of the reasons
for the inconsistency. Moreover, we also found that the m/
z drift in the IMAC3 array through time was less than
0.1%, which manifested the reproducibility of this tech-
nique.
SELDI-TOF MS Failed to Discriminate CRC Patients from 
Control Conditions
To identify serum proteins and polypeptides that are sig-
nificantly different between CRC and the control serum
samples, we carried out peak detection with BMW soft-
ware after normalizing peak intensities to the total ion
current. Seventeen out of 92 peaks from CRC patients
were selected, which could be used to distinguish these
samples from those from non-cancerous controls in the
training and test sets.
The BPS classification algorithm identified a series of clas-
sification models which were constructed with one or
more protein peaks with varying classification accuracy.
The best classification tree with the highest classification
accuracy was constructed using four masses at m/z 3961,
5343, 2869 and 3827 to generate five terminal nodes (Fig-
ure 2A). The four peaks achieved a sensitivity of 91.03%
and a specificity of 73.03% in diagnosing CRC in the
training set.
The best decision tree was then used to predict the pres-
ence or absence of CRC in serum samples in the blinded
test set. Of the 76 cases of CRC, 16 were misclassified by
the decision tree. And among the 95 controls, 4 of the 61
non-cancerous controls, 24 of the 34 patients with other
cancer types were misjudged as CRC, respectively. The
sensitivity and specificity of the decision tree classification
were thus 78.95% (60/76) and 70.53% (67/95), respec-
tively. But 70.59% (24/34) of the control cancers were
misjudged; this decision tree thus failed to separate CRC
patients from control cancers.
SELDI-TOF MS Discriminates Cancer Patients from Non-
cancerous Controls
To investigate if SELDI-TOF MS can distinguish cancer
patients from a non-cancerous control, the second train-
ing set was used to construct a diagnostic serum protein
pattern. The best classification tree with the highest classi-
fication accuracy was constructed using two masses at m/z
3961 and m/z 5200 to generate three terminal nodes (Fig-
ure 2B). The two peaks achieved a sensitivity of 98.20%
and a specificity of 89.29% in diagnosing cancer in the
training set. Their mass spectra were shown in Figure 3A.Page 4 of 9
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between cancer and non-cancerous controls. In the
blinded testing set, the sensitivity and specificity of the
decision tree classification to separate cancer patients
from the non-cancerous controls were 96.36% (106/110)
and 90.16% (55/61), respectively. The mean intensity of
the m/z 3961 and m/z 5200 peaks are of great difference in
the cancer group and the non-cancer control group (Table
4). Figure 3B, C demonstrates the distribution of the two
peaks of each patient group. The ROC and AUC values of
each peak and their combination in the 171 cases of the
blind test set are shown in Figure 4.
SELDI-TOF MS Failed to Discriminate Patients with CRC 
from Control Cancers
To investigate if SELDI-TOF MS can distinguish patients
with CRC from those with other cancer types, serum spec-
imens in the training set were used to construct a third
diagnostic serum protein pattern. The BPS algorithm
failed in building a classifier to reliably separate CRC from
the control cancers. The best selected tree performed
poorly in the blinded test set with a sensitivity of 60.53%
and specificity of 58.82%.
Discussion
Newly discovered biomarkers must be validated before
ultimately used in a clinical setting. As a validation bench-
mark, Pepe et al [20] proposed five phases in develop-
ment of biomarkers for early detection of cancer: 1)
preclinical exploratory studies, 2) clinical assay develop-
ment for clinical established disease, 3) retrospective lon-
gitudinal repository studies, 4) prospective screening
studies, and 5) cancer control studies. The validation
effort described in this report addresses phase 2 and 3 and
reflects the special challenges of using mass spectrometry-
based protein profiling as a biomarker for early detection
of CRC.
In the design of this study, we considered previous con-
cerns regarding the propensity for bias in multiplex profil-
ing methods [25], the inherent limitations of protein
profiling [26], the effects of pre-analytic sample handling
[21] and the related concerns of potential bias and gener-
alizability of this platform [27,28].
We carefully designed the current study to avoid biases in
sampling and analysis. To minimize possible sampling
bias, we collected samples from four different hospitals in
Beijing and selected control subjects with cancers other
than CRC, with benign tumor or inflammatory diseases,
or healthy volunteers. To minimize the preanalytic sam-
ple handling effects, we developed a standard sample
processing procedure. The specimens were randomly
assigned to training set and blinded testing set with possi-
ble confounders such as age, sex, TNM stage and diagnos-
tic groups from each hospital balanced in the two sets.
However, there were differences in patient contributions
from individual hospital in terms of age, sex and disease
Raw peak spectra generated by two generations IMAC arraysFigur  1
Raw peak spectra generated by two generations IMAC arrays. QC-30 and QC-3, a same QC sample on IMAC 30 and 
IMAC 3 in year 2008, respectively; N-04 and C-04, a normal and a cancer sample on IMAC 3 in year 2004.Page 5 of 9
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hospital in the two sets were not evenly distributed. These
differences were due to distinct nature of patient catch-
ment of each hospital, e.g., specialized cancer hospital
versus general medicine hospitals, and represent a poten-
tial limitation in our study.
In this study, we failed to use our previously discovered
classifiers [19] to detect CRC, which may be due to the
internal difference between the IMAC 3 ProteinChip and
its second generation, IMAC 30, for, we have shown in
this report that peaks generated from these two Protein-
Chip arrays differed greatly in their capacity to capture
protein peaks including number and intensities. Moreo-
ver, we failed to find a classifier that reliably identifies
patients with CRC from the mixed cohort of patients with
other cancer types and control subjects or any classifier
that was able to distinguish CRC from other cancer types.
We were thereby unable to confirm the promising results
reported previously [17-19], which could be seen as phase
1 studies for the discovery of specific biomarkers for CRC.
Recently, the Genitourinary Collaboration Group of the
American National Cancer Institute Early Detection
Research Network reported a failure in using SELDI-TOF
MS whole serum proteomic profiling with IMAC surface
to specifically detect prostate cancer [29]. Their work gave
us a model for biomarker studies. In their initial study,
they found this technique could distinguish prostate can-
cer patients from benign prostate hyperplasia and healthy
men [10]. Encouraged by this finding, they conducted a
strict validation process. In the first stage of validation,
Decision tree algorithmFigure 2
Decision tree algorithm. N, the number of specimens; M, the molecular weight. (A) Decision tree analysis to identify CRC 
and control specimens. If the peak intensity of an analyzed sample is below the cut-off value at the m/z in the node, the sample 
proceeds to the left. If not, it proceeds to the right. The cut off value of the peaks were 23.57, 17.42, 3.31 and 0.39, respec-
tively. Red bar, CRC; Blue bar, non-cancerous control. (B) Classification of cancer vs. non-cancerous control specimens by the 
decision tree algorithm. The cut off value of the peaks were 21.745 and 14.969, respectively. Red bar, cancer; Blue bar, non-
cancerous control.
Table 4: Different intensities of m/z 3960 and m/z 5200 in patients with cancer and non-cancerous control
Peaks Intensity (mean ± SD) * P
m/z 3960 < 0.0001
Cancer (n = 221) 8.87 ± 6.97
Non-cancerous Control (n = 117) 42.49 ± 14.89
m/z 5200 < 0.0001
Cancer (n = 221) 19.27 ± 15.16
Non-cancerous Control (n = 117) 7.59 ± 7.58
*Student's t test.Page 6 of 9
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Detection of two proteins in the mass pattern of serumFigure 3
Detection of two proteins in the mass pattern of serum. (A) Representative mass spectra showing the two peaks of the 
classifier at m/z 3961 and m/z 5200. The top two spectra were cancer, and the bottom two spectra were non-cancerous con-
trol. (B, C) Cluster plots generated using IMAC 30 ProteinChip for the two peaks of interest. Dotted line, mean peak intensity.
BMC Cancer 2009, 9:287 http://www.biomedcentral.com/1471-2407/9/287they proved the platform reproducibility of SELDI-TOF
MS over time and across laboratories [30]. When they
went further to the second and third stages, they were able
to identify deficiencies and implement improvements
[29,31]. In one of their reports [31], bias in sample collec-
tion protocols (i.e., the samples were not collected under
a same strict process) were discovered and a uniform pro-
cedure in sample preparation was recommended.
Based on these reports, our study design avoided potential
biases in sample colleting procedures by using a uniform
protocol; we did not have differences in patient ethnical
background that may compromise the study; we
attempted and succeeded to randomize and evenly dis-
tributed patients and subjects among the majority of key
characteristics.
One should not conclude from this current study that a
particular method does not work or that conclusions from
previous studies were wrong. In fact, there is increasing
evidence that serum proteomic analysis may ultimately be
turned into valuable clinical tools [29]. But the discovery
process is multi-staged, often meets with challenges, and
requires vigorous validation. We have demonstrated that
the SELDI-TOF MS approach with IMAC30 described in
this study has limited diagnostic value for CRC. We sug-
gest that greater attention be paid to choices of specimens
used in evaluating merit of subsequent studies. Meticu-
lous study design including sample cohort construction is
essential and may influence study conclusions. We also
suggest that all previous and forthcoming biomarkers
should be subjected to equally extensive and rigorous val-
idation. This statement calls into question how to accom-
modate many previous biomarker discovery efforts with
hard to obtain "ideal" specimens. This is a serious chal-
lenge for biomarker discovery, as all experimental
approaches are subject to false discovery from biased spec-
imens.
However, we were able to generate a classifier consisting
of two peaks that distinguishes patients with cancers from
non-cancerous controls, with promising diagnosis effi-
ciency. The m/z 3961 peak was down-regulated in the can-
cer specimens, and the m/z 5200 up-regulated. This
classifier separated CRC specimens from non-cancerous
controls as effectively as other previously reported classifi-
ers [17-19]. But the two peaks were not CRC-specific; they
could not separate CRC from other cancer types. As
chance is low for a patient to get two or more types of can-
cers, this classifier may have potential use in the detection
of possible recurrence of CRC after treatment like CEA,
but with higher sensitivity and specificity than CEA. Such
validation efforts are underway in ongoing studies.
At the moment, we have yet to decode the protein identity
associated with these two peaks of interest. Based on this
early stage finding, we are in the process of enriching these
peaks in an attempt to eventually learn the identity of
these peaks. In the meantime we are also using the SELDI
platform to further validate the potential prognostic or
diagnostic value of these peaks. Once validated, decoding
of the two peaks would open up more options for conven-
ient future usage.
Conclusion
In summary, bias in serum specimens of early studies, dif-
ferences in study design, and limitations of proteins
detected by SELDI-TOF MS in unfractionated serum may
explain the inability of this study to identify patients with
CRC; meanwhile, the internal difference between the
IMAC3 and IMAC30 arrays made it impossible to repro-
duce and validate our previous findings. However, this
technique may have potential use in monitoring the
relapse of CRC after treatment, and we are conducting a
prospective program for that.
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